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UGT1A3 and Sex Are Major Determinants 
of Telmisartan Pharmacokinetics—A 
Comprehensive Pharmacogenomic Study
Päivi Hirvensalo1,2, Aleksi Tornio1,2 , Terhi Launiainen1,2, Maria Paile-Hyvärinen1,2, Tuija Tapaninen1,2 ,  
Mikko Neuvonen1,2, Janne T. Backman1,2  and Mikko Niemi1,2,*
To investigate how variability in multiple pharmacokinetic genes associates with telmisartan exposure, we 
determined telmisartan single-dose (40 mg) pharmacokinetics and sequenced 379 genes in 188 healthy volunteers. 
Intronic UGT1A variants showed the strongest associations with the area under the plasma concentration-time 
curve from zero hours to infinity (AUC0–∞) and peak plasma concentration (Cmax) of telmisartan. These variants were 
strongly linked with the increased function UGT1A3*2 allele, suggesting that it is the causative allele underlying 
these associations. In addition, telmisartan plasma concentrations were lower in men than in women. The UGT1A3*2 
was associated with a 64% and 63% reduced AUC0-∞ of telmisartan in UGT1A3*2 heterozygous and homozygous 
men, respectively (P = 1.21 × 10−16 and 5.21 × 10−8). In women, UGT1A3*2 heterozygosity and homozygosity were 
associated with 57% (P = 1.54 × 10−11) and 72% (P = 3.31 × 10−15) reduced AUC0-∞, respectively. Furthermore, 
a candidate gene analysis suggested an association of UGT1A3*3 and the SLCO1B3 c.767G>C missense variant 
with telmisartan pharmacokinetics. A genotype score, which reflects the effects of sex and genetic variants on 
telmisartan AUC0–∞, associated with the effect of telmisartan on diastolic blood pressure. These data indicate that 
sex and UGT1A3 are major determinants and suggest a role for OATP1B3 in telmisartan pharmacokinetics.
Telmisartan is an angiotensin II receptor antagonist for treatment 
of hypertension.1 Uridine diphosphate-glucuronosyltransferase 
(UGT) 1A3 metabolizes telmisartan extensively to an acyl-glu-
curonide metabolite, which is the only telmisartan metabolite 
found in humans.2,3 UGT1A1, 1A7, 1A8, and 1A9 may also con-
tribute to telmisartan glucuronidation.3 Furthermore, in vitro 
studies have suggested the involvement of OATP1B3 (encoded 
by SLCO1B3) and 2B1 (encoded by SLCO2B1) transporters in 
the cellular uptake and P-gp/MDR1 (encoded by ABCB1) in the 
cellular efflux of telmisartan.4–7 Telmisartan acyl-glucuronide is 
a substrate of OATP1B3 and it is eliminated mainly by biliary 
excretion.2,8,9
High interindividual variability exists in the pharmacokinetics 
of telmisartan and low exposure to telmisartan is associated with 
poor blood pressure-lowering effect.10–12 Telmisartan is usually 
effective with a 40 mg daily dose, but a significant proportion of 
patients require a higher dose or combination treatment to achieve 
sufficient blood pressure control.13 For optimal therapy, it would 
be important to understand the sources of variability in the re-
sponse to antihypertensive medication.
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 Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 High interindividual variability exists in the pharmacoki-
netics of telmisartan. There are no comprehensive studies 
evaluating how variability in multiple pharmacokinetic genes 
associates with telmisartan exposure. 
WHAT QUESTION DID THIS STUDY ADDRESS?
 This study investigated how genetic variants associate with 
telmisartan single-dose pharmacokinetics in healthy volunteers. 
WHAT THIS STUDY ADD TO OUR KNOWLEDGE?
 This study shows that the UGT1A3*2 and *3 alleles 
are associated with reduced telmisartan exposure and the 
SLCO1B3 c.767G>C missense variant with increased tel-
misartan exposure. Based on the results, genotype scores 
were generated to predict telmisartan pharmacokinetics in 
men and women with different combinations of UGT1A3 
and SLCO1B3 variants. 
HOW THIS MIGHT CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
 This knowledge might aid in identifying individuals 
with increased risk of insufficient telmisartan exposure 
and impaired blood pressure-lowering response with the 40 
mg dose. This may aid in individualizing antihypertensive 
therapy. 
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There are few previous studies on the associations of genetic 
variants on the pharmacokinetics of telmisartan with relatively 
small sample sizes, but comprehensive studies are lacking. In two 
of the studies, either the UGT1A3*2 or the UGT1A1*28 allele was 
associated with significantly reduced plasma concentrations of tel-
misartan.3,14 In addition, one small study suggested an association 
between the ABCC2 c.-24C>T (rs717620) single nucleotide vari-
ation (SNV) and telmisartan peak plasma concentration (Cmax).
15 
On the other hand, variants in, for example, CYP2C8, CYP2C9, 
UGT2B7, SLCO1B3, ABCB1, and ABCG2 have not been associ-
ated with telmisartan pharmacokinetics.3,14,16,17 The aim of this 
study was to evaluate how variations in 379 pharmacokinetic genes 
associate with telmisartan pharmacokinetics.
METHODS
A total of 188 healthy unrelated white Finnish volunteers participated in 
the study after giving written informed consent. Their health was con-
firmed by medical history, clinical examination, and laboratory tests. 
Participants were not on any continuous medication nor were tobacco 
smokers. The study was approved by the Coordinating Ethics Committee 
of the Hospital District of Helsinki and Uusimaa (record number 
267/13/03/00/2011) and the Finnish Medicines Agency Fimea (EudraCT 
number 2011-004645-40). Of the participants, 91 were women and 97 
men. Their mean ± SD age was 24 ± 4 years, height 174 ± 9 cm, body 
weight 69 ± 12 kg, and body mass index 22.8 ± 2.6 kg/m2.
Telmisartan pharmacokinetics and pharmacodynamics
After an overnight fast, each participant ingested a 40  mg dose of 
telmisartan (Micardis tablet; Boehringer Ingelheim International 
GmbH, Ingelheim am Rhein, Germany) with 150  mL of water at 8 
am. Standardized meals were served at 4, 7, and 10 hours after telmis-
artan ingestion. Timed blood samples (4–9 mL each) were collected 
to light-protected EDTA tubes prior to and 0.5, 1, 1.5, 2, 3, 4, 5, 7, 9, 
12, 24, and 48 hours after telmisartan administration. Tubes were im-
mediately placed on ice. Plasma was separated within 30 minutes and 
stored at −70°C until analysis. Systolic and diastolic blood pressures 
were measured in a sitting position with an automatic oscillometric 
blood pressure monitor (Omron Healthcare Europe BV, Hoofddorp, 
The Netherlands) before and at 4, 12, and 24  hours after telmisar-
tan ingestion. The pharmacodynamic variables, the average change in 
diastolic and systolic blood pressure, were calculated by dividing the 
incremental area under the blood pressure-time curve from time 0 to 
24 hours with 24 hours.
Telmisartan and telmisartan acyl-(β-D-)glucuronide plasma concen-
trations were quantified using a Nexera X2 ultra-high-performance liquid 
chromatograph (Shimadzu, Kyoto, Japan) coupled to a Qtrap 5500 mass 
spectrometer (ABSciex, Foster City, CA). Plasma samples were pretreated 
using a Phree phospholipid removal plate (Phenomenex, Torrance, CA) 
according to the manufacturer’s instructions. In brief, plasma and acetoni-
trile containing the internal standards were mixed in a ratio of 1:5 (v/v), 
and the mixture was allowed to incubate for 10 minutes at room tempera-
ture. The sample mixture was then filtered through the cartridge, diluted 
with mobile phase (A), and delivered to the ultra-high-performance liq-
uid chromatography system. Telmisartan and telmisartan acyl-glucuro-
nide were separated on a Kinetex Biphenyl (2.6 µm, 2.1 mm × 100 mm; 
Phenomenex) using a gradient elution. Mobile phase consisted of 10 mM 
ammonium formate (pH 3.2, adjusted with formic acid) (A) and aceto-
nitrile (B). The mobile phase gradient was a linear ramp from 30% B to 
97% B over 1 minute, followed by 0.5 minutes at 97% B on hold, and an 
equilibration step back to the starting composition. The flow rate and 
the column temperature were maintained at 350 µL/min and 30°C, and 
the injection volume was 5 µL. Isotope-labeled analogs served as internal 
standards for both analytes. The mass spectrometer was operated in a 
positive polarity mode and the targeted mass-to-charge ratio (m/z) ion 
transitions were 515–276 and 691–515 for telmisartan and telmisar-
tan acyl-glucuronide. The lower limits of quantification were 0.3  ng/
mL and 0.1  ng/mL, respectively. The day-to-day precision values (coef-
ficients of variation) for both compounds were below 15% and accuracy 
within ± 15%, except for the lower limits of quantification, for which both 
precision and accuracy were within 20%.
The areas under the plasma concentration-time curve from 0 hours to 
infinity (AUC0–∞), Cmax, and the elimination half-life (t1/2) values were 
calculated for telmisartan and telmisartan acyl-glucuronide with stan-
dard noncompartmental methods using Phoenix WinNonlin, version 6.3 
(Certara, Princeton, NJ).
DNA sequencing and genotyping
Genomic DNA was extracted from EDTA blood samples using the 
Maxwell 16 LEV Blood DNA Kit on a Maxwell 16 Research auto-
mated nucleic acid extraction system (Promega, Madison, WI). A total 
of 379 pharmacokinetic genes, comprising phase I and II metabolizing 
enzymes, influx and efflux drug transporters, and regulatory proteins, 
were selected to be studied.18–20 These genes ± 20 kb, were completely 
sequenced in the study participants using targeted massive parallel se-
quencing at the Technology Centre at Institute for Molecular Medicine 
Finland (Helsinki, Finland).21 NEBNext DNA Sample Prep protocol 
(New England BioLabs, Ipswich, MA) was used for library preparation 
and the NimbleGen SeqCap EZ Choice protocol (Roche Sequencing, 
Pleasanton, CA) for target enrichment capture. Sequencing was done 
on the Illumina HiSeq2000 platform with 100  bp paired-end reads 
(Illumina, San Diego, CA). Quality control, short read alignment, and 
variant calling and annotation were carried out using an in-house devel-
oped pipeline.21 Mean coverage depth was 37.2X. Coverage depth ≥ 10X, 
Hardy–Weinberg equilibrium P < 3.15 × 10−7 (Bonferroni correction), 
and proportion missing ≤ 0.05 were used as quality thresholds. A total 
of 46,064 SNVs with minor allele frequency (MAF) ≥ 0.05 passed these 
criteria and were included in the statistical analysis. In order to verify 
genotype calls and to supplement missing data, all study participants 
were genotyped with TaqMan genotyping assays on a QuantStudio 12K 
Flex Real-Time PCR System for the UGT1A rs13401281, rs3821242, 
rs4663969, rs6715325, rs6431625, rs45449995, rs4148323, and 
rs3064744 sequence variations (Thermo Fisher Scientific, Waltham, 
MA).18,22 Call identity with sequencing data was 99.5% for rs6715325 
and 100% for all other SNVs. In case of discordant results, genotypes 
obtained by sequencing were used in the statistical analysis.
Statistical analysis
The number of participants was estimated to be sufficient to detect an 
effect size of f2 larger than 0.2 with two predictors in multiple linear 
regression analysis, with a power >  80% (Bonferroni corrected α level 
1.09  ×  10−6). The data were analyzed with the statistical programs 
JMP Genomics 8.2 (SAS Institute, Cary, NC) and IBM SPSS 22.0 for 
Windows (Armonk, NY). The pharmacokinetic variables were logarith-
mically transformed before analysis.23 Sex and body weight were tested as 
demographic covariates for pharmacokinetic data using stepwise linear 
regression analysis, with P value thresholds of 0.05 for entry and 0.10 for 
removal. Possible associations of genetic variants with pharmacokinetic 
variables were investigated using linear regression analysis fixed for sig-
nificant demographic covariates with a stepwise approach. A Bonferroni 
corrected P value threshold of 1.09 × 10−6 was used for the 379 gene and 
thresholds of 0.05 for entry and 0.10 for removal for the candidate gene 
analysis. Additive coding was used for genetic variants in the 379 gene 
analysis and both additive and dummy variable coding in the candidate 
gene analysis. Haplotype computations for UGT1A gene were performed 
with PHASE version 2.1.1.24,25 Statistical comparisons of proportions 
were done using the Fisher’s exact test. Possible correlation of telmisartan 
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AUC with the change in blood pressure during 24 hours was investigated 
using partial correlation analysis controlling for baseline blood pressure. 
Comparison of the change in blood pressure during 24 hours between 
genotype scores was investigated with analysis of variance, with baseline 
blood pressure as a covariate and P value < 0.05 considered statistically 
significant. Pharmacokinetic data are given as geometric means with geo-
metric coefficients of variation and ranges, geometric SDs, or 90% con-
fidence intervals (CIs). Pharmacodynamic data are given as arithmetic 
means with 95% CIs and proportions with 95% CIs.
RESULTS
Telmisartan pharmacogenomics
Among the 188 healthy volunteers, the AUC0–∞ and Cmax of 
telmisartan varied 49-fold and 31-fold, respectively, and those 
of telmisartan acyl-glucuronide 18-fold and 17-fold, respectively 
(Table 1). Both telmisartan AUC0–∞ and Cmax were larger in 
women than in men. In addition, body weight was a significant 
covariate for telmisartan Cmax. When entering both sex and 
body weight as independent variables in the regression analysis 
for telmisartan AUC0–∞, sex (P  =  0.005) but not body weight 
(P = 0.405) remained significantly associated. This indicates that 
the association of sex is independent of the weight.
In a stepwise linear regression analysis, which tested the 
associations of 46,064 SNVs with MAF of at least 0.05, the 
rs6715325 SNV, located between the UGT1A4 and UGT1A3 
first exons, showed the strongest association with the AUC0–∞ 
of telmisartan (Table 2, Figure 1). The AUC0–∞ was 46% 
(P  =  1.81  ×  10−22) smaller per copy of the variant allele. 
Furthermore, the rs2361501 SNV, located after UGT1A3 first 
exon, showed the strongest association with telmisartan Cmax, 
which was 26% (P = 4.00 × 10−7) smaller per copy of the variant 
allele. After adjusting for the rs6715325 or rs2361501 variant, 
no other variants remained associated with telmisartan AUC0–∞ 
or Cmax at the Bonferroni corrected significance level. The 
investigated genetic variants were not significantly associated 
with the t1/2 of telmisartan.
Similar to parent telmisartan, telmisartan acyl-glucuronide 
Cmax was significantly associated with intronic SNVs located 
around UGT1A3 first exon. The strongest association was 
observed with four SNVs (rs13401281, rs11891311, rs7564935, 
and rs11888459) in complete linkage disequilibrium with each 
other. The Cmax was 39% (P = 6.25 × 10
−11) higher per copy of the 
variant allele (Table 2). After adjusting for any one of these vari-
ants, no other variants remained statistically significantly associ-
ated with the Cmax. The investigated variants were not significantly 
associated with the AUC0–∞ or t1/2 of telmisartan acyl-glucuronide. 
The telmisartan acyl-glucuronide/telmisartan AUC0–∞ ratio also 
showed the strongest association with a UGT1A variant (Table 2).
Linkage disequilibrium and haplotype analysis
In order to identify the causative SNVs underlying the associa-
tion of the top noncoding UGT1A SNVs (rs6715325, rs2361501, 
rs13401281, and rs4663969) with telmisartan pharmacokinetic 
variables, we next investigated the linkage disequilibrium profile 
and computed haplotypes across the UGT1A gene. This was done 
for the top noncoding SNVs and the missense and functional vari-
ants (MAF ≥ 0.01) of the UGT1As, which metabolize telmisartan 
in vitro (UGT1A1, 1A3, 1A7, 1A8, and 1A9; Figure 2).3 All the 
top noncoding SNVs were strongly linked with each other as well 
as with the two UGT1A3 c.31T>C (p.Trp11Arg, rs3821242) and 
c.140T>C (p.Val47Ala, rs6431625) missense SNVs, which define 
the UGT1A3*2 allele (Figure 2a). The top SNVs were also in a rel-
atively strong linkage disequilibrium with the UGT1A1*28 allele 
(rs3064744, c.-54_-53insTA, TA6>TA7) and with the UGT1A7 
c.622T>C (p.Trp208Arg, rs11692021) missense SNV.
Altogether, 25 haplotypes were inferred in the haplotype com-
putation (Figure 2b). The top noncoding SNVs were present in 
Table 1 Pharmacokinetic variables of telmisartan and telmisartan acyl-glucuronide in 188 healthy volunteers and the 
effects of significant demographic covariates on these variables
Variable
Geometric 
mean CV Range Demographic covariate Effect (90% CI)a P value Adjusted R2
Telmisartan
Cmax, ng/mL 35 80% 5.2–165 Body weight
Sex
−14.2% (−18.7%, −9.5%)
31.9% (9.5%, 59.0%)
4.01 × 10−6
0.0150
0.25
0.27
Tmax, hour
b 1.5 — 0.5−9 —
AUC0–∞, ng·hour/mL 308 84% 37–1797 Sex 55.9% (31.7%, 84.6%) 2.26 × 10
−5 0.09
t1/2, hour 18 41% 6.7–83 Body weight −4.2% (−6.8%, −1.6%) 9.41 × 10
−3 0.03
Telmisartan acyl-glucuronide
Cmax, ng/mL 4.4 58% 1.2–19.4 Body weight −10.7% (−13.8%, −7.5%) 2.54 × 10
−7 0.13
Tmax, hour
b 0.75 — 0.5−12 —
AUC0–∞, ng·hour/mL 74 50% 18−318 Body weight −7.7% (−10.5%, −4.7%) 3.76 × 10
−5 0.08
t1/2, hour 20 58% 7.9–94 Sex 18.5% (4.3%, 34.7%) 0.0296 0.02
Telmisartan acyl  
glucuronide/ telmisartan 
AUC0–∞ ratio
0.24 73% 0.05–1.4 Sex −20.1% (−31.7%, −6.7%) 0.018 0.03
AUC0–∞, area under the plasma concentration-time curve from 0 hour to infinity; CI, confidence interval; CV, geometric coefficient of variation; Cmax, peak plasma 
concentration; Tmax concentration peak time; t1/2, elimination half-life.
aPer 10% increase in body weight; sex: women vs. men. bTmax data given as median.
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haplotypes which contained UGT1A3*2 or UGT1A3*3. In addi-
tion, the rs2361501 SNV was present in the same haplotype with 
UGT1A3*6. Altogether, the UGT1A3*2 allele was present in 10, 
UGT1A3*3 in 4, and UGT1A3*6 in 1 of the 25 inferred haplo-
types. The sum of frequencies was 0.39 for the UGT1A3*2, 0.061 
for UGT1A3*3, and 0.019 for the UGT1A3*6 containing haplo-
types. The most frequent haplotype (n = 98; MAF 0.26) contained 
the UGT1A3*2, UGT1A7*3, and UGT1A1*28 alleles.
Candidate gene analysis
Due to the risk of false negative associations with the conser-
vative Bonferroni correction in the primary analysis, we next 
carried out a candidate gene analysis for telmisartan AUC0–∞ 
without correction for multiple testing. In this analysis, we in-
cluded missense and functional variants with MAF of ≥ 0.01 in 
genes suggested to be involved in telmisartan pharmacokinetics 
(UGT1A3, UGT1A1, UGT1A7, UGT1A8, UGT1A9, SLCO1B3, 
SLCO2B1, ABCB1, and ABCC2; Table S1). In the analysis, 
UGT1A3*2 was associated with a 48% (P = 3.82 × 10−22) and 
UGT1A3*3 with a 28% (P  =  7.01  ×  10−3) reduced AUC0–∞ 
per copy of the allele, and SLCO1B3 c.767G>C (p.Gly256Ala, 
rs60140950) with a 22% (P  =  0.0392) increased telmisartan 
AUC0–∞ per copy of the minor allele (Table 3). Because of link-
age disequilibrium throughout the whole UGT1A locus, we 
repeated the candidate gene analysis using the inferred UGT1A8-
1A9-1A7-1A3-1A1 haplotypes with MAF ≥  0.01 (Figure 2b). 
All the haplotypes, which contained UGT1A3*2, were associ-
ated with reduced AUC0–∞ of telmisartan (Table S2).
Interestingly, the UGT1A3*2 allele lacked gene-dose effect es-
pecially in men and thus the log-additive regression model seemed 
to overestimate the AUC0–∞ of heterozygous UGT1A3*2 car-
riers. We, therefore, repeated the candidate gene analysis with 
UGT1A3*2 divided to four dummy variables representing the 
heterozygous and homozygous men and women. In this analysis, 
UGT1A3*2 heterozygosity and homozygosity in men were asso-
ciated with a 64% (P = 1.21 × 10−16) and 63% (P = 5.21 × 10−8) 
reduced telmisartan AUC0–∞, respectively (Table 3). In women, 
the UGT1A3*2 heterozygosity and homozygosity were associated 
with 57% (P = 1.54 × 10−11) and 72% (P = 3.31 × 10−15) reduced 
AUC0–∞, respectively. Entering body weight as a covariate in addi-
tion to sex did not change the results.
To further investigate the roles of UGT variants in telmisartan 
glucuronidation, we next carried out a candidate gene analysis 
for telmisartan acyl-glucuronide/telmisartan AUC0–∞ ratio with 
UGT1A3*2 dummy variables and other UGT1A3 and UGT1A1, 
UGT1A7, UGT1A8, and UGT1A9 variants. UGT1A3*2 hetero-
zygosity and homozygosity in men were associated with a 177% 
(P  =  3.13  ×  10−27) and 293% (P  =  2.25  ×  10−18) increased tel-
misartan acyl-glucuronide/telmisartan AUC0–∞ ratio, respectively 
(Table S3). In women, the UGT1A3*2 heterozygosity and homo-
zygosity were associated with 116% (P = 8.59 × 10−16) and 250% 
(P = 1.19 × 10−21) increased telmisartan acyl-glucuronide/telmis-
artan AUC0–∞ ratio, respectively.
To predict telmisartan AUC0–∞ in men and women with dif-
ferent combinations of UGT1A3 and SLCO1B3 genotypes, we 
calculated genotype scores (GS) using the UGT1A3*2 dummy Ta
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variable candidate gene linear regression model with the following 
equation:
Where M is male and F is female, UGT1A3*2 factor is 0.36 for 
heterozygous men, 0.37 for homozygous men, 0.42 for heterozy-
gous women, 0.28 for homozygous women, and 1 for noncarriers 
of UGT1A3*2, and n is the number of variant alleles (0, 1, or 2) of 
UGT1A3*3 and SLCO1B3 c.767G>C (Figures 3 and 4). The GS 
is 1.00 in men who do not carry any of the variants. For others, the 
score shows the fold difference in telmisartan AUC0–∞ compared 
with 1.00.
Pharmacodynamics
A total of 65% and 23% of individuals with GS of below 0.5 and 
between 0.5 and 0.8 had AUC0–∞ values below 229 ng·hour/mL, 
which was found in a previous study to be the AUC0–∞ value 
giving 50% of telmisartan maximum effect (Figure 3).12 The 
respective percentages in individuals with GS between 0.8 and 
1.25, and above 1.25 were 6% and 3%. Diastolic blood pressure de-
creased 1.3 mmHg (95% CI, 0.05, 2.5 mmHg) less in individuals 
GStelmisartan=1.47
0(M) or 1(F)
×UGT1A3∗2 factor×0.74n(UGT1A3∗3)
×1.23n(SLCO1B3c.767G>C)
Figure 1 The associations of 46,064 SNVs in 379 pharmacokinetic genes with telmisartan (a) area under the plasma concentration-time 
curve from zero hours to infinity (AUC0–∞) adjusting for sex and (b) the peak plasma concentration (Cmax) adjusting for sex and body weight (left 
panel). The Y-axes describe the negative logarithm of the P value for each single nucleotide variation (SNV) and the horizontal lines indicate 
the Bonferroni corrected significance level of 1.09 × 10−6. The X-axes show individual SNVs grouped by protein function. The geometric 
mean ± geometric SD AUC0–∞ and body weight adjusted Cmax values grouped by sex and the top UGT1A SNVs rs6715325 and rs2361501 
(right panel). [Colour figure can be viewed at wileyonlinelibrary.com]
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Figure 2 (a) Linkage disequilibrium of the top noncoding SNVs and missense and functional variants of the UGT1As, which metabolize 
telmisartan in vitro. (b) UGT1A haplotypes inferred with missense and functional variants, and top noncoding UGT1A SNVs. Intronic variations 
are depicted in blue and missense variations in red. The *-alleles are defined on the basis of missense variations within each UGT1A enzyme. 
The UGT1A7 allele containing the c.352G>T (p.Asp118Tyr, rs140814031) SNV together with c.387T>G, c.392G>A, and c.622T>C SNVs has 
not been named before and is here given tentatively the name UGT1A7*15.49,50 For clarity, only rs13401281 of the four completely linked 
telmisartan acyl-glucuronide peak plasma concentration (Cmax) top SNVs (rs13401281, rs11891311, rs7564935, and rs11888459) is 
presented in this figure. MAF, minor allele frequency; SNV, single-nucleotide variation. [Colour figure can be viewed at wileyonlinelibrary.com]
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with GS below 0.8 than in those with GS above 0.8 (P = 0.042; 
Figure 3). The average change in systolic blood pressure was not 
significantly associated with the GS (data not shown). Telmisartan 
AUC0–∞ correlated negatively with the average change in diastolic 
(r  =  −0.16; P  =  0.034) and systolic blood pressures (r  =  −0.19; 
P = 0.008).
Table 3 Results of the candidate gene analyses on telmisartan AUC0–∞
Pharmacokinetic 
variable Covariate/SNV
Effecta
P value
Adjusted R2 for 
each stepAverage (%) 90% CI
Telmisartan AUC0–∞ Sex 58.6 38.3, 81.9 9.79 × 10
−8 0.087
(Log-additive model) UGT1A3*2 −48.5 −53.2, −43.2 3.82 × 10−22 0.447
UGT1A3*3 −28.2 −41.2, −12.2 7.01 × 10−3 0.464
SLCO1B3 c.767G>C (rs60140950) 21.7 4.1, 42.4 0.0392 0.475
Telmisartan AUC0–∞ Sex 47.2 20.6, 79.7 1.58 × 10
−3 0.087
(UGT1A3*2 dummy 
variables)
UGT1A3*2 heterozygous men −63.6 −69.6, −56.3 1.21 × 10−16 0.227
UGT1A3*2 homozygous women −71.6 −77.7, −63.9 3.31 × 10−15 0.321
UGT1A3*2 heterozygous women −57.3 −64.9, −48.1 1.54 × 10−11 0.439
UGT1A3*2 homozygous men −63.2 −72.5, −50.8 5.21 × 10−8 0.505
UGT1A3*3 −25.8 −38.2, −11.0 7.47 × 10−3 0.519
SLCO1B3 c.767G>C (rs60140950) 23.1 6.7, 42.0 0.0172 0.532
AUC0–∞, area under the plasma concentration-time curve from zero hour to infinity; CI, confidence interval; SNV, single nucleotide variation
aPer minor allele copy or per dummy variable; sex: women vs. men.
Figure 3 (a) The geometric mean ± geometric SD area under the plasma telmisartan concentration-time curve from zero hours to infinity (AUC0–∞) 
values grouped by genotype scores (GS). The UGT1A3*1 allele includes all other UGT1A3 alleles than UGT1A3*2 and *3. (b) GS for individuals with 
different genotype combinations. UGT1A3 and SLCO1B3 reference genotypes are depicted with white, heterozygous with gray, and homozygous 
variant genotypes with black rectangles. The estimated population frequencies of the genotype combinations were obtained from the 1000 
Genomes Project Data.18,48 (c) The percentage of individuals (95% confidence interval (CI)) with AUC0–∞ < 229 ng·hour/mL in different GS groups. 
(d) The average change (95% CI) in diastolic blood pressure during 24 hours after telmisartan administration in GS groups < 0.8 and ≥ 0.8.
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DISCUSSION
In this study, we investigated the associations of variations in 379 
genes with telmisartan pharmacokinetics in 188 healthy volun-
teers. Noncoding variants in the UGT1A gene showed the stron-
gest associations with telmisartan pharmacokinetics. These top 
variants were strongly linked with the UGT1A3*2 and UGT1A3*3 
alleles, which provides a plausible mechanism for the association. 
Both UGT1A3*2 and UGT1A3*3 were associated with reduced 
systemic exposure to telmisartan. In addition, a missense variant 
in SLCO1B3 was associated with increased telmisartan exposure. 
Moreover, telmisartan exposure was significantly lower in men 
than in women. Based on these results, we constructed a scoring 
system to predict telmisartan plasma exposure in men and women 
with different combinations of genetic variants.
In this study, the UGT1A3*2 allele was associated with a mark-
edly reduced telmisartan AUC and explained more than 40% of 
its interindividual variability. These results are in line with previ-
ous studies showing associations between UGT1A3*2 or linked 
UGT1A variants, such as UGT1A1*28, and reduced telmisartan 
exposure,3,14,26 and indicate that metabolism via UGT1A3 is the 
main route of telmisartan elimination. In human liver samples, the 
UGT1A3*2 allele has been associated with increased mRNA and 
protein expression of UGT1A3.18,27 In addition to telmisartan, the 
UGT1A3*2 allele has been associated with increased metabolism 
of other UGT1A3 substrates, namely montelukast, atorvastatin, 
and febuxostat.18,27,28 The causal variant in this haplotype has not 
yet been identified, however. The haplotype carrying UGT1A3*2 
harbors many noncoding SNVs located around the first exon 
of UGT1A3,18 which might, for example, influence UGT1A3 
mRNA transcription. Another explanation could be induction of 
UGT1A3 expression by bilirubin, whose intrahepatic concentra-
tion should be increased in individuals carrying the UGT1A3*2-
linked UGT1A1*28.3
In the candidate gene analysis, also the UGT1A3*3 allele was as-
sociated with decreased telmisartan AUC. The effect of this allele 
was, however, smaller than that of UGT1A3*2 and explained only 
1–2% of the interindividual variability in telmisartan exposure. In 
previous studies with relatively small numbers of UGT1A3*3 car-
riers, the allele has not affected UGT1A3 mRNA or protein ex-
pression in human liver samples.18,27 In vitro studies on the effects 
of UGT1A3.3 on glucuronidation activity have been inconsistent, 
with studies showing either reduced or unchanged enzyme activ-
ity.29–31 Given the low allele frequency of UGT1A3*3 and the rela-
tively weak association with telmisartan exposure, the result needs 
confirmation in future studies.
In accordance with the associations with parent telmisartan, 
the UGT1A3*2 allele was associated with increased telmisartan 
acyl-glucuronide Cmax and telmisartan acyl-glucuronide/telmisar-
tan AUC ratio. In theory, the increased metabolite/parent com-
pound AUC ratio could be explained by either increased formation 
or reduced elimination of the metabolite, or both. Given that the 
UGT1A3*2 allele was associated with a reduced AUC and thus an 
increased oral clearance of telmisartan, increased metabolite for-
mation is the most probable explanation. The increased Cmax of 
telmisartan acyl-glucuronide in association with the UGT1A3*2 
allele is likely explained by formation of the metabolite during the 
first pass. Despite a strong association with the AUC of parent tel-
misartan, the UGT1A3*2 allele was not associated with the AUC 
of the acyl-glucuronide metabolite. This indicates that UGT1A3*2 
increases the rate of glucuronidation of telmisartan, but that the 
total amount of glucuronide formed is not changed. This is consis-
tent with glucuronidation being the exclusive route of telmisartan 
elimination.
In addition to UGT1A3, which metabolizes telmisartan with 
the highest affinity in vitro, telmisartan is a substrate of UGT1A1, 
UGT1A7, UGT1A8, and UGT1A9.3 All UGT1A enzymes are 
encoded by the UGT1A gene in chromosome 2.32 They share 
exons 2–5, but have unique first exons. Strong linkage disequilib-
rium patterns span the entire UGT1A gene.18 In the present study, 
we fully sequenced the whole UGT1A gene. Of the variants in the 
other candidate UGT1As, the UGT1A1*28 and UGT1A7*3 al-
leles are strongly linked with UGT1A3*2. The UGT1A1*28 allele 
has been associated with decreased glucuronidation of UGT1A1 
substrates due to significantly decreased UGT1A1 protein expres-
sion.33–35 Moreover, the UGT1A7*3 allele has been associated 
with decreased function of UGT1A7 in vitro.36 After adjusting 
for the UGT1A3 effect, no other UGT1A variants, including 
UGT1A1*28 and UGT1A7*3, were significantly associated with 
telmisartan AUC. Similarly, in the haplotype-based analysis, 
the UGT1A1*28 and UGT1A7*3 alleles did not associate inde-
pendently with telmisartan pharmacokinetics (Table S2). Taken 
together, these data indicate that genetic variability in UGT1A 
enzymes other than UGT1A3 is not of major importance for tel-
misartan pharmacokinetics.
In this study, the UGT1A3*2 allele seemed to lack a clear gene-
dose effect on telmisartan AUC and Cmax. That is, men showed 
no difference and women showed only a relatively small difference 
between UGT1A3*2 homozygotes and heterozygotes. No obvious 
explanation exists for these findings. However, linkage between 
Figure 4 Geometric mean (90% confidence interval (CI)) plasma 
concentrations of telmisartan after a single 40 mg oral dose of 
telmisartan in 188 healthy volunteers with different combinations 
of UGT1A3 and SLCO1B3 genotypes. The insets depict the same 
data on a semilogarithmic scale. The volunteers were grouped 
according to the genotype score (GS) as follows: GS < 0.50 (n = 80), 
GS ≥ 0.50; < 0.80 (n = 43), GS ≥ 0.80; ≤ 1.25 (n = 34), and 
GS > 1.25 (n = 31).
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UGT1A3*2 and UGT1A1*28 and a role of UGT1A1 in intesti-
nal telmisartan metabolism may play a role. It is notable, that the 
effects of the UGT1A1*28 allele are generally much more pro-
nounced in homozygotes than in heterozygotes,33–35 whereas those 
of UGT1A3*2 are usually seen already in heterozygotes.18,27 In the-
ory, the effects of UGT1A1*28 might thus counteract the effects of 
UGT1A3*2 on telmisartan pharmacokinetics in UGT1A3*2/*2–
UGT1A1*28/*28 homozygotes.
Considering that telmisartan pharmacokinetics strongly 
depends on UGT1A3 activity, it could be susceptible to 
UGT1A3-mediated drug-drug interactions. Interestingly, ni-
soldipine has increased the AUC of telmisartan by 132%.37 
In human liver microsomes, nisoldipine inhibits the glucu-
ronidation of estradiol,38 mediated by UGT1A1, UGT1A3, 
UGT1A8, UGT1A10, and UGT2B7.39 Further studies are 
required to determine whether nisoldipine inhibits UGT1A3. 
Telmisartan could be a useful index substrate for UGT1A3-
mediated drug-drug interactions.
Telmisartan has been suggested to be a relatively selective sub-
strate of OATP1B3, an influx transporter expressed on the baso-
lateral membrane of hepatocytes.4 In the candidate gene analysis, 
the SLCO1B3 c.767G>C missense SNV was associated with in-
creased telmisartan AUC, with a 22% increase per minor allele 
copy. However, this SNV explained only 1% of the interindividual 
variability in telmisartan exposure. There seems to be no previous 
studies investigating the associations of this SNV with telmisartan 
or other OATP1B3 substrate pharmacokinetics in humans. The 
SIFT and PolyPhen in silico prediction tools suggest the c.767G>C 
SNV to be deleterious.40,41 In one in vitro study, however, this 
SNV did not significantly affect the uptake of the OATP1B3 sub-
strate cholecystokinin-8.42 A recent in vitro study suggested that 
OATP2B1 would play a more important role than OATP1B3 in 
the hepatic uptake of telmisartan.5 In our study, SNVs in SLCO2B1 
were not, however, associated with telmisartan pharmacokinetics. 
The analysis included, for example, the c.601G>A SNV associated 
previously with 3S,5R-fluvastatin and the c.1457C>T SNV associ-
ated previously with 3S,5R-fluvastatin, fexofenadine, and celipro-
lol pharmacokinetics.43–45
In accordance with previous studies,10,16,26 the AUC and Cmax of 
telmisartan were significantly lower in men than in women. Body 
size did not explain this difference. Our finding that the telmis-
artan acyl-glucuronide/telmisartan AUC ratio was higher in men 
than in women suggests that the difference could be due to higher 
telmisartan glucuronidation capacity in men. Interestingly, no sex 
difference seemed to exist in telmisartan AUC and Cmax in individ-
uals homozygous for UGT1A3*2.
Telmisartan plasma concentration–time profiles are character-
ized by a biexponential decline after the Cmax, with a rapid initial 
distribution followed by a prolonged terminal elimination phase.10 
Of note, no appreciable drug accumulation occurs during multiple 
dosing. This suggests that our pharmacokinetic results after a sin-
gle telmisartan dose can be extrapolated to continuous treatment. 
However, advanced age, concomitant diseases, and other medi-
cations may increase variability in telmisartan pharmacokinetics 
in patients with hypertension as compared with the healthy vol-
unteers of the present study. Nevertheless, the effects of UGT1A 
variants seem to be similar in patients with hypertension and 
healthy volunteers.26 This suggests that the effects of genetic vari-
ants on telmisartan pharmacokinetics in healthy volunteers can be 
extrapolated to patients with hypertension.
The maximum antihypertensive effect of telmisartan is usually 
attained within 4–8 weeks after the start of treatment, but some ef-
fect can be seen already 3 hours after the first dose in patients with 
hypertension.11 In general, the antihypertensive effect of telmisar-
tan is much more pronounced in hypertensive than in normoten-
sive individuals. Nevertheless, in our study in normotensive healthy 
volunteers, the average change in diastolic and systolic blood pres-
sures correlated negatively with telmisartan AUC. Moreover, a low 
GS was associated with the weak diastolic blood pressure-lower-
ing effect of telmisartan. One should keep in mind, however, that 
these pharmacodynamic results should not be directly extrapolated 
to patients with hypertension. The finding that the average change 
in systolic blood pressure was not significantly associated with the 
GS may be explained by greater variation in systolic than diastolic 
blood pressure.
A previous angiotensin II challenge study in healthy volunteers 
showed that telmisartan efficacy is concentration-dependent. The 
telmisartan AUC0–∞ value giving 50% of the maximum effect was 
estimated to be 229 ng × hour/mL.12 In the present study, the pro-
portion of individuals having AUC0–∞ values below 229 ng·hour/
mL after a 40  mg dose increased along with a decreasing GS. In 
the treatment of hypertension, the effective dose of telmisartan is 
usually 40 mg once daily, but a significant proportion of patients 
require 80  mg daily due to poor efficacy.13 Because the effect of 
telmisartan is dose-dependent and concentration-dependent, and 
there is large variability in telmisartan exposure, it is probable that 
inadequate efficacy with the 40  mg dose may, in some cases, be 
due to insufficient plasma concentrations. On the other hand, al-
though telmisartan is usually well-tolerated,46,47 it is possible that 
increased exposure predisposes to hypotension or other adverse ef-
fects. The GS might aid in finding the right telmisartan doses for 
patients with hypertension.
The participants of this study were white Finnish volunteers, 
among whom the allele frequency of UGT1A3*2 was 0.39. The 
UGT1A3*2 allele is generally very common in European (0.32), 
Sub-Saharan African (0.56), and South-Asian (0.42) popula-
tions, but less common in East Asians (0.12).18 On the contrary, 
UGT1A3*3 is more common in South and East Asians (MAF 0.20 
and 0.18) as compared with Europeans (0.07) and Sub-Saharan 
Africans (0.086). These interethnic differences in UGT1A3 allele 
frequencies lead to differences in the distributions of telmisar-
tan GSs among populations (Figure 3).18,48 In previous studies 
in Asian individuals, the UGT1A3*2 allele or linked UGT1A 
variants have been associated with a similar effect on telmisartan 
pharmacokinetics, as was seen in the present study.3,14,26 This sug-
gests that our findings can be extrapolated to other populations.
In conclusion, these results indicate that genetic variants 
of UGT1A3 associate strongly with the pharmacokinetics of 
telmisartan. Due to lower plasma concentrations, carriers of 
UGT1A3*2 may be at an increased risk of poor blood pres-
sure-lowering efficacy of telmisartan. The results also suggest 
an association of SLCO1B3 c.767G>C variant with telmisartan 
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exposure. The generated GS may aid in individualizing treat-
ment with telmisartan.
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